DDInter1853 DDInter462
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Tretinoin {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Tretinoin {u} (Compound) downregulates {v} (Gene) HIST1H2BK
HIST1H2BK {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Tretinoin {u} (Compound) upregulates {v} (Gene) TSC22D3
TSC22D3 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Tretinoin {u} (Compound) downregulates {v} (Gene) VDAC1
VDAC1 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Tretinoin {u} (Compound) upregulates {v} (Gene) TLR4
TLR4 {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Tretinoin {u} (Compound) binds {v} (Gene) GPRC5A
GPRC5A {u} (Gene) is downregulated by {v} (Compound) Dabrafenib
Tretinoin {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Tretinoin {u} (Compound) resembles {v} (Compound) Isotretinoin
Isotretinoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Tretinoin {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Tretinoin {u} (Compound) downregulates {v} (Gene) HIST1H2BK
HIST1H2BK {u} (Gene) is regulated by {v} (Gene) CDKN1A
CDKN1A {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Tretinoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Tretinoin (Compound) downregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Dabrafenib (Compound)
Tretinoin (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Dabrafenib (Compound)
Tretinoin (Compound) downregulates VDAC1 (Gene) and VDAC1 (Gene) is downregulated by Dabrafenib (Compound)
Tretinoin (Compound) upregulates TLR4 (Gene) and TLR4 (Gene) is downregulated by Dabrafenib (Compound)
Tretinoin (Compound) binds GPRC5A (Gene) and GPRC5A (Gene) is downregulated by Dabrafenib (Compound)
Tretinoin (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Tretinoin (Compound) resembles Isotretinoin (Compound) and Iso
Tretinoin (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Tretinoin (Compound) downregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is regulated by CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Dabrafenib (Compound)